MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
*Funding: Infectious Disease
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Catalio Capital Management
Portfolio Companies: Catalio
Sensei Biotherapeutics Inc. (NASDAQ: SNSE)*
Organization & Developments: Sensei
Parents
Sensei Biotherapeutics Inc. (NASDAQ: SNSE)*
Children
2022: Sensei and Instil Bio let go large chunks of workforces, shift pipelines
2022: Sensei Biotherapeutics (SNSE) Investor Presentation -Slideshow_ seekingalpha.com
Clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.
Pipeline of cancer immunotherapies, which are based on engineered bacteriophages
Sensei Bio (NASDAQ: SNSE) is a clinical-stage oncology company developing a novel, personalized cancer vaccine platform based on bacteriophages, small viruses that typically infect bacteria.
Sensei will apply its bacteriophage technology to a wide range of cancers starting with prostate, head and neck, and hematologic indications.
Sensei’s unique technology allows them to generate bespoke versions of an inactivated bacteriophage decorated with patient-specific neoantigens to stimulate an immune response against tumors.
Jumps
*Key People: Sensei
Finance & Acquisitions: Sensei